Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 24, 2026

Efficacy and Safety of Selinexor Combined with VRD in Newly Diagnosed Multiple Myeloma with EMD: A Phase 2 Trial.

View Full Paper
Ask AI
Bookmark
Share

Authors

YJYuanyuan JinXCXin ChengXZXuezhong Zhang

Discussion

Loading...

Member takes

Overview

Phase 2 trial evaluates selinexor with VRD showing high response rates in newly diagnosed multiple myeloma with EMD, suggesting effective treatment options.

Key Points

  • This trial aimed to assess the efficacy and safety of selinexor combined with VRD in patients with newly diagnosed multiple myeloma and extramedullary disease.
  • Multicenter, open-label, single-arm phase II trial
  • 30 patients enrolled, with 29 treated forming modified intention-to-treat cohort
  • Induction treatment of four 28-day cycles with selinexor, bortezomib, lenalidomide, and dexamethasone
  • Primary endpoint was overall response rate during induction
  • Overall response rate achieved was 89.7%, with 58.6% achieving stringently complete response
  • Imaging showed regression of extramedullary disease in 89.7% of patients
  • 12-month progression-free survival rate was 87.9% and overall survival rate was 96.3%
  • Grade ≥3 adverse events occurred in 37.3%, primarily thrombocytopenia and neutropenia

Cite This Study

Jin et al. (2026) studied this question.

synapsesocial.com/papers/697461a8bb9d90c67120b8cfhttps://doi.org/10.1182/bloodadvances.2025018945
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study2026
  2. 2Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial2025
  3. 3Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with extramedullary disease: a multicenter study2024
  4. 4Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study2024 · 14 citations
  5. 5Navigating the Post‐ <scp>BCMA</scp> / <scp>GPRC5D</scp> Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis2026 · 2 citations